European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading
Japan's Ministry Of Health, Labour And Welfare Has Accepted For Review GSK's New Drug Application For Blenrep (Belantamab Mafodotin) In Combination With Bortezomib Plus Dexamethasone Or Pomalidomide Plus Dexamethasone For Relapsed Or Refractory...
Brooke Shields Partners With GSK to Educate Adults 50 and Older About Their Shingles Risk
ITeos Therapeutics Shares Rise on Positive Data From Lung Cancer Study
Reported Saturday, ITeos Therapeutics Announced Follow-Up Interim Data From GALAXIES Lung-201 Phase 2 Platform Study Sponsored By GSK, For Belrestotug+Dostarlimab Doublet In Previously Untreated, Unresectable, Locally Advanced Or Metastatic PD-L1 High...
Goldman Sachs Reaffirms Their Hold Rating on GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK) Gets a Hold From Barclays
GSK, ITeos Lung Cancer Therapy Outperforms Jemperli in Mid-stage Trial
Moderna's Faces 'Material Headwinds' on RSV, COVID, RBC Says
Analyst Issues Sell Rating for GlaxoSmithKline Amid Market Share and Litigation Concerns
Blenrep (Belantamab Mafodotin) in Combination Receives Breakthrough Therapy Designation in China for Treatment of Relapsed/refractory Multiple Myeloma
GSK's HSV Vaccine Study Fails to Meet Primary Efficacy Goal
Fulcrum Crashes as GSK-partnered Lead Program Fails
Earlier Today, GSK Announced Headline Results Of A Phase 2 Trial For Its MRNA Seasonal Influenza Vaccine Program, Demonstrating A And B Strain Immune Responses Relative To Standard Of Care In Both Younger And Older Adults
GSK's MRNA Flu Vaccine Advances to Late-Stage Clinical Development After Positive Trial Results
GSK Reaches Another Settlement in Zantac Litigation
GSK Confirms It Has Reached A Confidential Settlement With Mr. Isaac Dixon, Resolving The Prostate Cancer Case Filed In Illinois State Court; GSK Does Not Admit Any Liability In This Settlement. The Case Will Now Be Dismissed.
GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech
Earlier Today GSK's Phase 1/2 Proof-Of-Concept Study Of GSK3943104 Did Not Meet The Study's Primary Efficacy Objective, Hence It Will Not Progress To Phase 3 Studies
GSK's HPV Vaccine Misses Main Goal in Early-to-Mid Stage Study